findmyKOL
Clinical trialNCT04745559Active, not recruitingPhase 2Interventional

Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy

SponsorH. Lee Moffitt Cancer Center and Research InstituteEnrollment26Diffuse Large-Cell LymphomaFollicular LymphomaHigh-grade B-cell Lymphoma (HGBCL)Primary Mediastinal Large B-Cell Lymphoma (PMBCL)Transformed Follicular Lymphoma (TFL)
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Moffitt Cancer Center

    Tampa, Florida, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
18 Feb 2021
Primary completion
31 Jul 2025
Completion
30 Jun 2027
Last update posted
29 Jan 2026
Registered enrollment
26
Registry id
NCT04745559

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.